Search

(1) Background: Many drugs possess poor bioavailability, and many strategies are available to overcome this issue. In this study, smartFilm technology, i.e., a porous cellulose matrix (paper), in which the active compound can be loaded onto in an amorphous state was utilised for oral administration to improve the solubility and bioactivity of a poorly soluble BSC class IV antibiotic. (2) Methods: Norfloxacin was used as the model drug and loaded into commercially available paper. The resulting norfloxacin-loaded smartFilms were transformed into smartFilm granules via wet granulation and the resulting norfloxacin-loaded smartFilm granules were transformed into norfloxacin-loaded tablets made from paper, i.e., smartFilm tablets. The crystalline state of norfloxacin was investigated, as well as the pharmaceutical properties of the granules and the tablets. The bioactivity of the smartFilm tablets was assessed in vitro and ex vivo to determine the antibacterial activity of norfloxacin. The results were compared to a physical mixture tablet that contained non-loaded paper granules and equal amounts of norfloxacin as a crystalline powder. (3) Results: Norfloxacin-loaded smartFilm granules and norfloxacin-loaded smartFilm tablets contained norfloxacin in an amorphous state, which resulted in an improved and faster release of norfloxacin when compared to the physical mixture tablet. The bioactivity was up to three times higher when compared to the physical mixture tablet. The ex vivo model was demonstrated to be a useful tool that allows for a fast and cost-effective discrimination between “good” and “bad” formulations. It provides realistic physiological conditions and can therefore yield meaningful, additional biopharmaceutical information that cannot be assessed in classical in vitro experiments. (4) Conclusions: smartFilm tablets are a promising, universal, industrially feasible and cost-effective formulation strategy for improved solubility and enhanced bioactivity of poorly soluble drugs.

Pancreatic cancer remains one of the most challenging malignancies to diagnose and treat effectively, resulting in poor patient outcomes due to late-stage detection and limited therapeutic options. The emergence of biosensors has revolutionized cancer diagnosis and therapy, providing new avenues for early detection and personalized treatment. This paper explores the development and integration of biosensors within a unique expert system for pancreatic cancer diagnosis and drug delivery automation. It discusses the principles, types, and applications of biosensors in pancreatic cancer diagnosis, their role in automating drug delivery, and the design of an expert system that leverages these technologies to enhance patient outcomes. [ABSTRACT FROM AUTHOR]

(1) Background: Many drugs possess poor bioavailability, and many strategies are available to overcome this issue. In this study, smartFilm technology, i.e., a porous cellulose matrix (paper), in which the active compound can be loaded onto in an amorphous state was utilised for oral administration to improve the solubility and bioactivity of a poorly soluble BSC class IV antibiotic. (2) Methods: Norfloxacin was used as the model drug and loaded into commercially available paper. The resulting norfloxacin-loaded smartFilms were transformed into smartFilm granules via wet granulation and the resulting norfloxacin-loaded smartFilm granules were transformed into norfloxacin-loaded tablets made from paper, i.e., smartFilm tablets. The crystalline state of norfloxacin was investigated, as well as the pharmaceutical properties of the granules and the tablets. The bioactivity of the smartFilm tablets was assessed in vitro and ex vivo to determine the antibacterial activity of norfloxacin. The results were compared to a physical mixture tablet that contained non-loaded paper granules and equal amounts of norfloxacin as a crystalline powder. (3) Results: Norfloxacin-loaded smartFilm granules and norfloxacin-loaded smartFilm tablets contained norfloxacin in an amorphous state, which resulted in an improved and faster release of norfloxacin when compared to the physical mixture tablet. The bioactivity was up to three times higher when compared to the physical mixture tablet. The ex vivo model was demonstrated to be a useful tool that allows for a fast and cost-effective discrimination between "good" and "bad" formulations. It provides realistic physiological conditions and can therefore yield meaningful, additional biopharmaceutical information that cannot be assessed in classical in vitro experiments. (4) Conclusions: smartFilm tablets are a promising, universal, industrially feasible and cost-effective formulation strategy for improved solubility and enhanced bioactivity of poorly soluble drugs. [ABSTRACT FROM AUTHOR]

Paper‐based electronics are emerging as a new class of technology with broad areas of application. Despite several efforts to fabricate new types of flexible electronic devices by screen printing of conductive paste, many of them are often nonbiodegradable, toxic, and expensive, limiting their practical use in bioresorbable paper‐based electronics. To address this need, a highly conductive and biodegradable bimodal conductive paste is developed using cost‐effective zinc‐based micro and nanoparticles with a facile low‐temperature sintering process compatible with paper substrates. The two‐step sintering process involves the removal of the insulating zinc oxide layer by spray coating acetic acid followed by a heat press sintering process to ensure the formation of highly packed and continuous metallic traces. The required conditions for the heat press sintering process are systematically studied using electrical, optical, and mechanical characterization techniques. The results of these investigations revealed an ultra‐packed microstructure with high electrical conductivity (0.5 × 105 S m−1) and low oxide content that is obtained with a heat press sintering setting of 220 °C for 60 s. Finally, as a proof of concept, the conductive paste with an optimized sintering process is used to fabricate a wearable wireless heater for remote‐controlled release of therapeutics. The controlled delivery of the system is validated in the practical and on‐demand delivery of antibiotics for eradicating commonly found bacteria such as Staphylococcus aureus in dermal wound infections. The biocompatibility of all the materials and manufacturing process is validated by NIH/3T3 fibroblast cells via MTT assay and live/dead staining. [ABSTRACT FROM AUTHOR]

Improved global access to novel age‐appropriate formulations for paediatric subsets, either of new chemical entities or existing drugs, is a priority to ensure that medicines meet the needs of these patients. However, despite regulatory incentives, the introduction to the market of paediatric formulations still lags behind adult products. This is mainly caused by additional complexities associated with the development of acceptable age‐appropriate paediatric medicines. This position paper recommends the use of a paediatric Quality Target Product Profile as an efficient tool to facilitate early planning and decision making across all teams involved in paediatric formulation development during the children‐centric formulation design for new chemical entities, or to repurpose/reformulate off‐patent drugs. Essential key attributes of a paediatric formulation are suggested and described. Moreover, greater collaboration between formulation experts and clinical colleagues, including healthcare professionals, is advocated to lead to safe and effective, age‐appropriate medicinal products. Acceptability testing should be a secondary endpoint in paediatric clinical trials to ensure postmarketing adherence is not compromised by a lack of acceptability. Not knowing the indications and the related age groups and potential dosing regimens early enough is still a major hurdle for efficient paediatric formulation development; however, the proposed paediatric Quality Target Product Profile could be a valuable collaborative tool for planning and decision making to expedite paediatric product development, particularly for those with limited experience in developing a paediatric product. [ABSTRACT FROM AUTHOR]

Older people are often affected by impaired organ and bodily functions resulting in multimorbidity and polypharmacy, turning them into the main user group of many medicines. Very often, medicines have not specifically been developed for older people, causing practical medication problems for them like limited availability of easy to swallow formulations, easy to open packaging and dosing instructions for enteral administration. In 2020, the European Medicines Agency (EMA) published a reflection paper 'Pharmaceutical development of medicines for use in the older population', which discusses how the emerging needs of an ageing European population can be addressed by medicines regulation. The paper intends to help industry to better consider the needs of older people during pharmaceutical/clinical medicines development by summarising data on the most relevant topics, providing early suggestions on how to move forward and prompting expert discussions and studies into knowledge gaps. Topics include patient acceptability, (dis)advantages of an administration route, formulation, dosage form, packaging, dosing device and user instruction. While the paper is directed at older people and the pharmaceutical industry, the reflections are also relevant to younger patients with similar disease‐related needs and of value to other stakeholders parties, e.g., healthcare professionals, academics, patients and caregivers, as the paper makes clear what can be expected from industry and where collaborative work is needed. This commentary provides an overview of the different steps in the development of the reflection paper, discusses points considered most controversial and/or subject to (multidisciplinary) expert discussions and indicates their value for real world clinical practice. [ABSTRACT FROM AUTHOR]

Paper devices have many advantages over other microfluidic devices. The paper substrate, from cellulose to glass fiber, is an inexpensive substrate that can be readily modified to suit a variety of applications. Milli- to micro-scale patterns can be designed to create a fast, cost-effective device that uses small amounts of reagents and samples. Finally, well-established chemical and biological methods can be adapted to paper to yield a portable device that can be used in resource-limited areas (e.g., field work). Altogether, the paper devices have grown into reliable analytical devices for screening low quality pharmaceuticals. This review article presents fabrication processes, detection techniques, and applications of paper microfluidic devices toward pharmaceutical screening. [ABSTRACT FROM AUTHOR]

Paper is a common material that is promising for constructing microfluidic chips (lab-on-a-paper) for diagnostics and drug delivery for biomedical applications. In the past decade, extensive research on paper-based microfluidics has accumulated a large number of scientific publications in the fields of biomedical diagnosis, food safety, environmental health, drug screening and delivery. This review focuses on the recent progress on paper-based microfluidic technology with an emphasis on the design, optimization and application of the technology platform, in particular for medical diagnostics and drug delivery. Novel advances have concentrated on engineering paper devices for point-of-care (POC) diagnostics, which could be integrated with nucleic acid-based tests and isothermal amplification experiments, enabling rapid sample-to-answer assays for field testing. Among the isothermal amplification experiments, loop-mediated isothermal amplification (LAMP), an extremely sensitive nucleic acid test, specifically identifies ultralow concentrations of DNA/RNA from practical samples for diagnosing diseases. We thus mainly focus on the paper device-based LAMP assay for the rapid infectious disease diagnosis, foodborne pathogen analysis, veterinary diagnosis, plant diagnosis, and environmental public health evaluation. We also outlined progress on paper microfluidic devices for drug delivery. The paper concludes with a discussion on the challenges of this technology and our insights into how to advance science and technology towards the development of fully functional paper devices in diagnostics and drug delivery. Unlabelled Image [ABSTRACT FROM AUTHOR]

In recent years, polymer-supported magnetic iron oxide nanoparticles (MIO-NPs) have gained a lot of attention in biomedical and healthcare applications due to their unique magnetic properties, low toxicity, cost-effectiveness, biocompatibility, and biodegradability. In this study, waste tissue papers (WTP) and sugarcane bagasse (SCB) were utilized to prepare magnetic iron oxide (MIO)-incorporated WTP/MIO and SCB/MIO nanocomposite particles (NCPs) based on in situ co-precipitation methods, and they were characterized using advanced spectroscopic techniques. In addition, their anti-oxidant and drug-delivery properties were investigated. Field emission scanning electron microscopy (FESEM) and X-ray diffraction (XRD) analyses revealed that the shapes of the MIO-NPs, SCB/MIO-NCPs, and WTP/MIO-NCPs were agglomerated and irregularly spherical with a crystallite size of 12.38 nm, 10.85 nm, and 11.47 nm, respectively. Vibrational sample magnetometry (VSM) analysis showed that both the NPs and the NCPs were paramagnetic. The free radical scavenging assay ascertained that the WTP/MIO-NCPs, SCB/MIO-NCPs, and MIO-NPs exhibited almost negligible antioxidant activity in comparison to ascorbic acid. The swelling capacities of the SCB/MIO-NCPs and WTP/MIO-NCPs were 155.0% and 159.5%, respectively, which were much higher than the swelling efficiencies of cellulose-SCB (58.3%) and cellulose-WTP (61.6%). The order of metronidazole drug loading after 3 days was: cellulose-SCB < cellulose-WTP < MIO-NPs < SCB/MIO-NCPs < WTP/MIO-NCPs, whereas the sequence of the drug-releasing rate after 240 min was: WTP/MIO-NCPs < SCB/MIO-NCPs < MIO-NPs < cellulose-WTP < cellulose-SCB. Overall, the results of this study showed that the incorporation of MIO-NPs in the cellulose matrix increased the swelling capacity, drug-loading capacity, and drug-releasing time. Therefore, cellulose/MIO-NCPs obtained from waste materials such as SCB and WTP can be used as a potential vehicle for medical applications, especially in a metronidazole drug delivery system. [ABSTRACT FROM AUTHOR]

This paper reviews the potential applications of nanorobots in oncology, cardiology, neurology, respiratory medicine, and nephrology, emphasizing their role in precision drug delivery, cancer therapy, diagnostic procedures, surgical interventions, and disease management. Nanorobots perform particular tasks with great accuracy and precision. They are capable of sensing the environment, transmitting signals to technicians, processing information, and exhibiting intelligence at the nanoscale. They are utilized for treating various illnesses in medical specialties such as cardiology, respiratory, neurology, nephrology, and ophthalmology. Nanorobots can be primarily used in surgery. The material characteristics, such as non-toxicity and biocompatibility, are critical for their safe interaction within the human body. Furthermore, various insertion methods, including intravenous and intra-tumoral injections, are explored. Future advancements are anticipated to enhance multifunctionality, targeting specificity, and integration with artificial intelligence, leading to more autonomous and efficient nanorobots. The integration of nanorobots in medical practice could revolutionize healthcare by offering minimally invasive, highly precise, and personalized treatment options, significantly improving patient outcomes and quality of life. [ABSTRACT FROM AUTHOR]

Biosensors integrated with artificial intelligence (AI) hold immense potential for transforming healthcare through rapid, automated diagnostics and precision therapeutics. This paper reviews the convergence of biosensing and AI towards developing smart biomedical systems. The fundamentals, historical evolution, and classification of biosensors are presented, highlighting key applications across infections, chronic illnesses, and environmental monitoring. Core AI concepts, including machine learning, neural networks, computer vision, and natural language processing, are discussed, along with their implementation to augment biosensor functionality, connectivity, point-of-care adoption, and laboratory automation. Promising research directions and real-world case studies applying AI-integrated biosensors for early diagnosis and drug delivery are discussed. The opportunities and challenges in advancing this synergistic technology are contemplated, underscoring the need for cross-disciplinary collaboration, clinical validation, ethical vigilance and supportive policy environments to successfully translate AI-biosensors into practical healthcare solutions. [ABSTRACT FROM AUTHOR]

To liberate society from its dependence on fossil‐based fuels and materials it is pivotal to explore components of renewable plant biomass in applications that benefit from their intrinsic biodegradability, safety, and sustainability. Lignin, a byproduct of the pulp and paper industry, is a plausible material for carrying various types of cargo in small‐ and large‐scale applications. Herein, possibilities and constraints regarding the physical–chemical properties of the lignin source as well as modifications and processing required to render lignins suitable for the loading and release of pesticides, pharmaceuticals, and biological macromolecules is reviewed. In addition, the technical challenges, regulatory and toxicological aspects, and future research needed to realize some of the promises that nano‐ and microscaled lignin materials hold for a sustainable future are critically discussed. [ABSTRACT FROM AUTHOR]

In recent years, polymer-supported magnetic iron oxide nanoparticles (MIO-NPs) have gained a lot of attention in biomedical and healthcare applications due to their unique magnetic properties, low toxicity, cost-effectiveness, biocompatibility, and biodegradability. In this study, waste tissue papers (WTP) and sugarcane bagasse (SCB) were utilized to prepare magnetic iron oxide (MIO)-incorporated WTP/MIO and SCB/MIO nanocomposite particles (NCPs) based on in situ co-precipitation methods, and they were characterized using advanced spectroscopic techniques. In addition, their anti-oxidant and drug-delivery properties were investigated. Field emission scanning electron microscopy (FESEM) and X-ray diffraction (XRD) analyses revealed that the shapes of the MIO-NPs, SCB/MIO-NCPs, and WTP/MIO-NCPs were agglomerated and irregularly spherical with a crystallite size of 12.38 nm, 10.85 nm, and 11.47 nm, respectively. Vibrational sample magnetometry (VSM) analysis showed that both the NPs and the NCPs were paramagnetic. The free radical scavenging assay ascertained that the WTP/MIO-NCPs, SCB/MIO-NCPs, and MIO-NPs exhibited almost negligible antioxidant activity in comparison to ascorbic acid. The swelling capacities of the SCB/MIO-NCPs and WTP/MIO-NCPs were 155.0% and 159.5%, respectively, which were much higher than the swelling efficiencies of cellulose-SCB (58.3%) and cellulose-WTP (61.6%). The order of metronidazole drug loading after 3 days was: cellulose-SCB < cellulose-WTP < MIO-NPs < SCB/MIO-NCPs < WTP/MIO-NCPs, whereas the sequence of the drug-releasing rate after 240 min was: WTP/MIO-NCPs < SCB/MIO-NCPs < MIO-NPs < cellulose-WTP < cellulose-SCB. Overall, the results of this study showed that the incorporation of MIO-NPs in the cellulose matrix increased the swelling capacity, drug-loading capacity, and drug-releasing time. Therefore, cellulose/MIO-NCPs obtained from waste materials such as SCB and WTP can be used as a potential vehicle for medical applications, especially in a metronidazole drug delivery system.

Cystic Fibrosis (CF) is a life-shortening, genetic disease that affects approximately 145,000 people worldwide. CF causes a dehydrated mucus layer in the lungs, leading to damaging infection and inflammation that eventually result in death. Nanoparticles (NPs), drug delivery vehicles intended for inhalation, have become a recent source of interest for treating CF and CF-related conditions, and many formulations have been created thus far. This paper is intended to provide an overview of CF and the effect it has on the lungs, the barriers in using NP drug delivery vehicles for treatment, and three common material class choices for these NP formulations: metals, polymers, and lipids. The materials to be discussed include gold, silver, and iron oxide metallic NPs; polyethylene glycol, chitosan, poly lactic-co-glycolic acid, and alginate polymeric NPs; and lipid-based NPs. The novelty of this review comes from a less specific focus on nanoparticle examples, with the focus instead being on the general theory behind material function, why or how a material might be used, and how it may be preferable to other materials used in treating CF. Finally, this paper ends with a short discussion of the two FDA-approved NPs for treatment of CF-related conditions and a recommendation for the future usage of NPs in people with Cystic Fibrosis (pwCF). [ABSTRACT FROM AUTHOR]

This paper introduces an architecture to improve the pharmaceutical supply chain's security by using the Internet of Things, semantic web, and blockchain. This architecture increases transparency and visibility of drug flows and improves the representation of the increasing amounts of data that have been generated from pharmaceutical supply chain transactions. The pharmaceutical companies have problems dealing with the complexity of their supply chains, which represent the full life cycle of drugs from extracting raw materials, production, distribution, tracking of drugs, and quality assurance to use by patients. They need to create an efficient, effective, transparent, immutable, and secured supply chains to achieve a competitive advantage in a fast-changing market. A proposed architecture which applies the semantic web technology is implemented to enhance the representation capability of the IoT-blockchain based pharmaceutical supply chain data by annotating them with semantically rich languages to conduct formal reasoning, and aggregating data from heterogeneous sources in easy way and an interoperable manner. The proposed architecture integrates IoT, blockchain, and semantic web to help pharmaceutical companies improving their supply chains in transit and storage, improving patient satisfaction, trust through transparency, preventing drug counterfeit and sharing and reusing knowledge related to the pharmaceutical supply chain with other systems. [ABSTRACT FROM AUTHOR]

The fight against infectious disease has remained an ever-evolving challenge in the landscape of healthcare. The ability of pathogens to develop resistance against conventional drug treatments has decreased the effectiveness of therapeutic interventions, and antibiotic resistance is recognized as one of the main challenges of our time. The goal of this systematic review paper is to provide insight into the research papers published on innovative nanosized drug delivery systems (DDSs) based on gentamycin and vancomycin and to discuss the opportunity of their repurposing through nano DDS formulations. These two antibiotics are selected because (i) gentamicin is the first-line drug used to treat suspected or confirmed infections caused by Gram-negative bacterial infections and (ii) vancomycin is used to treat serious Gram-positive bacterial infections. Moreover, both antibiotics have severe adverse effects, and one of the purposes of their formulation as nanosized DDSs is to overcome them. The review paper includes an introduction focusing on the challenges of infectious diseases and traditional therapeutic treatments, a brief description of the chemical and pharmacological properties of gentamicin and vancomycin, case studies from the literature on innovative nanosized DDSs as carriers of the two antibiotic drugs, and a discussion of the results found in the literature. [ABSTRACT FROM AUTHOR]

This paper explores the latest advancements in aerogel technology for antimicrobial therapy, revealing their interesting capacity that could improve the current medical approaches for antimicrobial treatments. Aerogels are attractive matrices because they can have an antimicrobial effect on their own, but they can also provide efficient delivery of antimicrobial compounds. Their interesting properties, such as high porosity, ultra-lightweight, and large surface area, make them suitable for such applications. The fundamentals of aerogels and mechanisms of action are discussed. The paper also highlights aerogels' importance in addressing current pressing challenges related to infection management, like the limited drug delivery alternatives and growing resistance to antimicrobial agents. It also covers the potential applications of aerogels in antimicrobial therapy and their possible limitations. [ABSTRACT FROM AUTHOR]

At the forefront of advanced material technology, radiation-induced hydrogels present a promising avenue for innovation across various sectors, utilizing gamma radiation, electron beam radiation, and UV radiation. Through the unique synthesis process involving radiation exposure, these hydrogels exhibit exceptional properties that make them highly versatile and valuable for a multitude of applications. This paper focuses on the intricacies of the synthesis methods employed in creating these radiation-induced hydrogels, shedding light on their structural characteristics and functional benefits. In particular, the paper analyzes the diverse utility of these hydrogels in biomedicine and agriculture, showcasing their potential for applications such as targeted drug delivery, injury recovery, and even environmental engineering solutions. By analyzing current research trends and highlighting potential future directions, this review aims to underscore the transformative impact that radiation-induced hydrogels could have on various industries and the advancement of biomedical and agricultural practices. [ABSTRACT FROM AUTHOR]